Anna Quattropani

Anna Quattropani is the Head of Non-Clinical Development and Medicinal Chemistry. She is responsible for all non-clinical development activities including medicinal chemistry, chemistry, manufacturing and controls (CMC), ADME, early safety pharmacology and toxicology. She also manages the small molecule intellectual property portfolio of the company.

Anna is an experienced Medicinal Chemist with more than 18 years of experience and a successful track record in the design and optimization of small molecules originating from high throughput screening, fragment discovery and knowledge-based design into drug candidates. During the past ten years, she has been working on a variety of neurodegenerative disease projects, designing and optimizing drug-like small molecules with CNS exposure for multiple sclerosis, Alzheimer’s disease and orphan tauopathies such as progressive supranuclear palsy.

Anna is inventor of several clinical molecules such as the O-GlcNAcase inhibitor ASN120290 for progressive supranuclear palsy and the oxytocin receptor antagonist Nolasiban that has entered Phase 3 clinical studies. Anna obtained her Ph.D. and M.S. in organic synthesis and organometallic chemistry at University of Geneva, Switzerland. She is the inventor of 34 patents and the author of 20 peer-reviewed publications.